Acute limb ischemia in COVID-19 patients despite therapeutic anticoagulation: Experience from Africa

Q4 Medicine
Fikremariam Melkeneh Alemayehu , Dawit Kebede Huluka , Tizazu Kebede Beyene , Azmera Gissila Aboye , Hiwotie Abebe Mesfin
{"title":"Acute limb ischemia in COVID-19 patients despite therapeutic anticoagulation: Experience from Africa","authors":"Fikremariam Melkeneh Alemayehu ,&nbsp;Dawit Kebede Huluka ,&nbsp;Tizazu Kebede Beyene ,&nbsp;Azmera Gissila Aboye ,&nbsp;Hiwotie Abebe Mesfin","doi":"10.1016/j.tru.2022.100128","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Hypercoagulability is a common complication seen in COVID-19 infection. However, arterial thrombosis such as acute limb ischemia (ALI) is far less common. Data on the incidence and nature of arterial thromboembolic complications in patients with COVID-19 is limited, originating from a few case reports and case series. Data in the African continent are very scarce.</p></div><div><h3>Method</h3><p>This is a case series of 10 patients with COVID-19 who developed ALI while on treatment at Eka Kotebe General Hospital, Addis Ababa, Ethiopia. All patients with ALI and COVID-19 admitted between February 1, 2021, and December 31, 2021, were retrospectively identified and reviewed. COVID-19 was confirmed by RT-PCR and ALI was confirmed by Doppler ultrasound and/or computed tomography angiography in the presence of clinical suspicion.</p></div><div><h3>Results</h3><p>A total of 3098 patients were hospitalized with confirmed COVID-19 during the study period. In a series of 10 patients, 8 (80%) males with a median age of 53.5 years were included. All except one (10%) had one or more risk factors for ALI and one had a ‘possible’ case of vaccine-induced thrombotic thrombocytopenia (VITT) associated with ALI. All were admitted with severe COVID-19 and most (80%) developed ALI during hospitalization (median of seven days from admission). The median duration between COVID-19 and ALI symptom onset was 14.5 days (IQR, 11–15). The majority (60%) were taking therapeutic anticoagulation at the time of ALI onset which is the standard of care for patients with severe disease. Five (50%) were successfully revascularized (median time of 3.5 days) and the rest underwent amputation. All survived and were discharged improved.</p></div><div><h3>Conclusion</h3><p>ALI can occur in the context of COVID-19 even while a patient is on therapeutic dose anticoagulation and in the absence of traditional risk factors. It is wise to be vigilant of this complication for timely intervention and better treatment outcomes.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666572722000323","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Hypercoagulability is a common complication seen in COVID-19 infection. However, arterial thrombosis such as acute limb ischemia (ALI) is far less common. Data on the incidence and nature of arterial thromboembolic complications in patients with COVID-19 is limited, originating from a few case reports and case series. Data in the African continent are very scarce.

Method

This is a case series of 10 patients with COVID-19 who developed ALI while on treatment at Eka Kotebe General Hospital, Addis Ababa, Ethiopia. All patients with ALI and COVID-19 admitted between February 1, 2021, and December 31, 2021, were retrospectively identified and reviewed. COVID-19 was confirmed by RT-PCR and ALI was confirmed by Doppler ultrasound and/or computed tomography angiography in the presence of clinical suspicion.

Results

A total of 3098 patients were hospitalized with confirmed COVID-19 during the study period. In a series of 10 patients, 8 (80%) males with a median age of 53.5 years were included. All except one (10%) had one or more risk factors for ALI and one had a ‘possible’ case of vaccine-induced thrombotic thrombocytopenia (VITT) associated with ALI. All were admitted with severe COVID-19 and most (80%) developed ALI during hospitalization (median of seven days from admission). The median duration between COVID-19 and ALI symptom onset was 14.5 days (IQR, 11–15). The majority (60%) were taking therapeutic anticoagulation at the time of ALI onset which is the standard of care for patients with severe disease. Five (50%) were successfully revascularized (median time of 3.5 days) and the rest underwent amputation. All survived and were discharged improved.

Conclusion

ALI can occur in the context of COVID-19 even while a patient is on therapeutic dose anticoagulation and in the absence of traditional risk factors. It is wise to be vigilant of this complication for timely intervention and better treatment outcomes.

抗凝治疗后COVID-19患者急性肢体缺血:来自非洲的经验
高凝是COVID-19感染的常见并发症。然而,动脉血栓形成,如急性肢体缺血(ALI)远不常见。关于COVID-19患者动脉血栓栓塞并发症的发生率和性质的数据有限,仅来自少数病例报告和病例系列。非洲大陆的数据非常少。方法本研究收集了10例在埃塞俄比亚亚的斯亚贝巴Eka Kotebe综合医院治疗期间发生ALI的COVID-19患者的病例系列。对2021年2月1日至2021年12月31日期间入院的所有ALI和COVID-19患者进行回顾性鉴定和回顾。在有临床怀疑的情况下,采用RT-PCR确诊COVID-19,采用多普勒超声和/或计算机断层扫描血管造影确诊ALI。结果研究期间共收治确诊COVID-19患者3098例。在10例患者中,8例(80%)为男性,中位年龄53.5岁。除一人(10%)外,所有人都有ALI的一个或多个危险因素,一人“可能”有与ALI相关的疫苗诱导的血栓性血小板减少症(VITT)病例。所有患者均因严重COVID-19入院,大多数(80%)在住院期间(入院后7天内中位数)发生ALI。COVID-19和ALI症状发作之间的中位持续时间为14.5天(IQR, 11-15)。大多数(60%)在ALI发病时正在服用治疗性抗凝治疗,这是重症患者的标准护理。5例(50%)成功重建血管(中位时间为3.5天),其余行截肢。全部存活,出院情况好转。结论在COVID-19背景下,即使患者正在使用治疗剂量的抗凝治疗,并且没有传统的危险因素,也可能发生ali。明智的做法是对这种并发症保持警惕,以便及时干预并获得更好的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Thrombosis Update
Thrombosis Update Medicine-Hematology
CiteScore
1.90
自引率
0.00%
发文量
33
审稿时长
86 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信